Cardiome Pharma said Oxypurinol failed the efficacy test in a study of 405 congestive heart failure patients. The 24-week study yielded no statistically significant benefits over placebo, didn't increase the time between hospitalizations, and didn't improve quality of life. CEO Bob Rieder said he was disappointed in the "unequivocal negative outcome" but will review the data before deciding the fate of the program.
- read this report from for more